|
1
|
Del Mastro L, Lambertini M, Bighin C,
Levaggi A, D'Alonzo A, Giraudi S and Pronzato P: Trastuzumab as
first-line therapy in HER2-positive metastatic breast cancer
patients. Expert Rev Anticancer Ther. 12:1391–1405. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Swain SM, Kim SB, Cortés J, Ro J,
Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A,
Knott A, et al: Overall survival benefit with pertuzumab,
trastuzumab, and docetaxel for HER2-positive metastatic breast
cancer in CLEOPATRA, a randomised Phase 3 study. Lancet Oncol.
14:461–471. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baselga J, Cortés J, Kim SB, Im SA, Hegg
R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al:
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast
cancer. N Engl J Med. 366:109–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lobbezoo DJ, van Kampen RJ, Voogd AC,
Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ,
Peters FP, van Riel JM, Peters NA, et al: Prognosis of metastatic
breast cancer subtypes: The hormone receptor/HER2-positive subtype
is associated with the most favorable outcome. Breast Cancer Res
Treat. 141:507–514. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Swain SM, Kim SB, Cortés J, Ro J,
Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A,
Knott A, et al: Pertuzumab, trastuzumab, and docetaxel for
HER2-positive metastatic breast cancer (CLEOPATRA study): Overall
survival results from a randomised, double-blind,
placebo-controlled, phase 3 study. Lancet Oncol. 14:461–471. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maciá Escalante S, Rodríguez Lescure A,
Sanz V Pons, Martínez Banaclocha N, Guillén Ponce C and Mena A
Carrato: A patient with breast cancer with hepatic metastases and a
complete response to herceptin as monotherapy. Clin Transl Oncol.
8:761–763. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Beda M, Basso U, Ghiotto C and Monfardini
S: When should trastuzumab be stopped after achieving complete
response in HER2-positive metastatic breast cancer patients?
Tumori. 93:491–492. 2007.PubMed/NCBI
|
|
9
|
Badulescu F, Badulescu A, Paul D, Popescu
CF and Florescu C: More than 9 years of continuous trastuzumab
treatment in metastatic breast cancer without cardiac toxicity: A
case report and literature review. Onco Targets Ther. 7:1911–1917.
2014.PubMed/NCBI
|
|
10
|
Artac M, Koral L, Toy H, Guler T, Boruban
MC and Altundag K: Complete response and long-term remission to
anti-HER2 combined therapy in a patient with breast cancer
presented with bone marrow metastases. J Oncol Pharm Pract.
20:141–145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ihnenfeld A, rciénega I, Imesch P, Fink D
and Dedes KJ: Prolonged complete remission of metastatic
HER2-positive breast cancer after continuous trastuzumab treatment:
A case report and review of the literature. Target Oncol.
10:297–301. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Syrios J, Dokou A and Tsavaris N:
Sustained complete remission of human epidermal growth factor
receptor 2-positive metastatic breast cancer in the liver during
long-term trastuzumab (Herceptin) maintenance therapy in a woman: A
case report. J Med Case Rep. 4:4012010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hsieh A, Pittman K, Patterson WK and
Townsend A: Can maintenance trastuzumab be stopped in patients with
HER2-positive metastatic breast cancer? BMJ Case Rep 2015.
pii:bcr2014207750. 2015.
|
|
14
|
Cardoso F, Harbeck N, Fallowfield L,
Kyriakides S and Senkus E; ESMO Guidelines Working Group, : Locally
recurrent or metastatic breast cancer: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23
Suppl 7:vii11–vii19. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Giordano SH, Temin S, Kirshner JJ,
Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo
AM, Krop I, Levinson J, et al: Systemic therapy for patients with
advanced human epidermal growth factor receptor 2-positive breast
cancer: American society of clinical oncology clinical practice
guideline. J Clin Oncol. 32:2078–2099. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cardoso F, Costa A, Senkus E, Aapro M,
André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso
MJ, et al: III ESO-ESMO international consensus guidelines for
advanced breast cancer (ABC 3). Ann Oncol. Feb 19–2017.(Epub ahead
of print). View Article : Google Scholar
|
|
17
|
Yeo B, Kotsori K, Mohammed K, Walsh G and
Smith IE: Long-term outcome of HER2 positive metastatic breast
cancer patients treated with first-line trastuzumab. Breast.
24:751–757. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Witzel I, Müller V, Abenhardt W, Kaufmann
M, Schoenegg W, Schneeweis A and Jänicke F: Long-term tumor
remission under trastuzumab treatment for HER2 positive metastatic
breast cancer-results from the HER-OS patient registry. BMC Cancer.
14:8062014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Luen SJ, Salgado R, Fox S, Savas P,
Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S
and Loi S: Tumour-infiltrating lymphocytes in advanced
HER2-positive breast cancer treated with pertuzumab or placebo in
addition to trastuzumab and docetaxel: A retrospective analysis of
the CLEOPATRA study. Lancet Oncol. 18:52–62. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yardley DA, Tripathy D, Brufsky AM, Rugo
HS, Kaufman PA, Mayer M, Magidson J, Yoo B, Quah C and Yood M
Ulcickas: Long-term survivor characteristics in HER2-positive
metastatic breast cancer from registHER. Br J Cancer.
110:2756–2764. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Harano K, Lei X, Gonzalez-Angulo AM,
Murthy RK, Valero V, Mittendorf EA, Ueno NT, Hortobagyi GN and
Chavez-MacGregor M: Clinicopathological and surgical factors
associated with long-term survival in patients with HER2-positive
metastatic breast cancer. Breast Cancer Res Treat. 159:367–374.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fiteni F, Villanueva C, Bazan F, Perrin S,
Chaigneau L, Dobi E, Montcuquet P, Cals L, Meneveau N, Nerich V, et
al: Long-term follow-up of patients with metastatic breast cancer
treated by trastuzumab: Impact of institutions. Breast. 23:165–169.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Murthy P, Kidwell KM, Schott AF, Merajver
SD, Griggs JJ, Smerage JD, Van Poznak CH, Wicha MS, Hayes DF and
Henry NL: Clinical predictors of long-term survival in
HER2-positive metastatic breast cancer. Breast Cancer Res Treat.
155:589–595. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gullo G, Zuradelli M, Sclafani F, Santoro
A and Crown J: Durable complete response following chemotherapy and
trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol.
23:2204–2205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Swain SM, Baselga J, Kim SB, Ro J,
Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A,
Heeson S, et al: Pertuzumab, trastuzumab, and docetaxel in
HER2-positive metastatic breast cancer. N Engl J Med. 372:724–734.
2015. View Article : Google Scholar : PubMed/NCBI
|
